Global Information
회사소개 | 문의 | 비교리스트

미국의 유방암 종양절제술 시장, 치료 비용, 기회 분석

US Breast Cancer Lumpectomy Market, Treatment Cost & Opportunity Analysis 2024

리서치사 KuicK Research
발행일 2018년 03월 상품 코드 617893
페이지 정보 영문 100 Pages
US $ 2,400 ₩ 3,007,000 Unprintable PDF by E-mail (Single User License)
US $ 2,800 ₩ 3,508,000 CD-ROM
US $ 3,500 ₩ 4,385,000 Hard Copy
US $ 4,400 ₩ 5,513,000 Printable PDF by E-mail (Multi-User License)

미국의 유방암 종양절제술 시장, 치료 비용, 기회 분석 US Breast Cancer Lumpectomy Market, Treatment Cost & Opportunity Analysis 2024
발행일 : 2018년 03월 페이지 정보 : 영문 100 Pages

미국의 유방암 종양절제술(Breast Cancer Lumpectomy) 시장을 분석했으며, 현재 시장 규모, 동향, 기회 및 시장 역학 분석, 향후 예측, 기회 및 주요 기업 개요 등을 정리하여 전해드립니다.

제1장 유방암·종양절제술의 서문

제2장 종양절제술 : 미국 유방암 치료 시장의 기회

  • 미국의 유방암 시장 규모
  • 미국의 유방암 발증률 증가
  • 종양절제술·방사선 치료의 조합 : 유방절제술과 동등한 효과

제3장 종양절제술 : 시술·관련 비용

  • 유방암 맘모그램 검사·생검 비용
  • 시술에 포함되는 비용
  • 종양절제술·유방절제술의 의료비 상환 분석
  • 종양절제술 후 비용
  • 비용 효과적인 종양절제술

제4장 종양절제술 유방암 치료의 현재 시장 현황·동향

  • 미국 여성 사이에서 유방암 검사가 증가
  • 임상 연구의 증가가 종양절제술의 우수한 효과를 증명

제5장 종양절제술 시장 분석 : 기술별

  • MarginProbe : 종양절제술을 개선할 수술중 기술
  • Savi Scout : 유방 위치 특정·수술 가이던스 시스템
  • Biozorb LP : 종양절제술 후 더 나은 미용적 결과

제6장 미국의 종양절제술 시장에 영향을 미치는 주요 발전

  • 조기 단계 유방암 부문에서 주요 산업의 포커스
  • 우수한 유방암 검사 기술의 도입과 종양절제술 시장에 대한 영향
  • 미국의 종양절제술 기술·제품이 세계 플랫폼으로 확대

제7장 신규·개선된 유방 영상 기술이 종양절제술 시장을 촉진

  • 디지털 유방단층촬영술(DBT)
  • 유방암 유전자 검사가 증가
  • 혁신적인 종양절제 기술의 FDA 인가

제8장 미국의 유방암 종양절제술 부문에 영향을 미치는 벤처 캐피탈리스트의 존재

제9장 Porter의 산업 분석

제10장 종양절제술 시장 분석 : 최종사용자별

  • 병원
  • 암연구·검사 센터

제11장 미국의 종양절제술 시장 역학

  • 시장 성장 촉진 파라미터
  • 시장 성장·수용성의 과제

제12장 종양절제술 시장 예측

제13장 경쟁 분석

  • Carl Zeiss Meditech
  • Cianna Medical
  • Clear Cut Medical
  • Dune Medical Devices
  • Endomagnetics
  • Focal Therapeutics
  • Hologic
  • iCAD
  • Medtronic
  • Sanarus
KSA 18.04.04

Report Highlights:

  • Lumpectomy Procedure & Cost Involved
  • Lumpectomy & Mastectomy Reimbursement Analysis
  • Lumpectomy Market Analysis by Technology
  • Presence of Venture Capitalist influencing the Market
  • Porter's Five Force Analysis
  • Lumpectomy Market Opportunity Projections: More Than US$ 10 Billion

Breast cancer is one of the most common forms of cancer globally with 99% of the breast cancer patients being women. Recent data indicates that about 266,120 new cases of invasive and 63390 cases of noninvasive breast cancer will occur by the end of 2018 in the US alone, making it a primary health concern for women in US where one in 8 women is bound to be diagnosed with breast cancer during her lifetime.

Inspite of alarming rates of breast cancer incidence, a decrease in breast cancer mortality has been observed in the last few years. Technological advancement in the healthcare industry and improvements in traditional surgical techniques have contributed immensely in the successful treatment of early stage breast cancer, saving the lives of millions of breast cancer affected women globally.

Removal of cancer effected breast, known as mastectomy is still the most preferred and effective method in treating early stage breast cancer (Stage 0, I, II & III). However, recent trends show that a majority of breast cancer affected patients are opting for less extreme approach in breast cancer treatment. Women in US currently show a high preference for breast conserving surgery that has led surgeons and oncologists to develop a novel and innovative alternative to mastectomy, widely popular as lumpectomy.

Lumpectomy is the removal of cancer affected lump or tumor from the breast while causing minimal tissue loss. This procedure aims at conserving the original shape and size of the breast while also ensuring the complete eradication of cancer cells. Additionally, a patient undergoing lumpectomy has been observed to have better outcome in post-surgical procedures such as breast reconstruction with better cost affectivity compared to mastectomy.

Lumpectomy was previously believed to be less effective than mastectomy. However, recent clinical studies have proved that lumpectomy followed by five to seven weeks of radiation therapy has better efficacy than mastectomy; which has led to a strong foundation of the lumpectomy market in the US with multiple factors fuelling its growth.

Key factors driving the growth of US lumpectomy market are the growing incidence of breast cancer and the rise in better breast cancer imaging methods such as the introduction of 3D tomography which have been immensely helpful in accurate and early detection of breast cancer lumps in dense breasts which remained undetected by traditional breast imaging techniques.

Lumpectomy specific devices such as marginprobe by dune medical devices for identification of the tumor and normal tissue margin, 'Savi scout' for breast localization and surgical guidance (which is bound to replace traditional wire localization technique) and 'Intrabeam' by Carl Zeiss Meditech for targeted radiation delivery are few of the important tools that are bound to improve the outcome of lumpectomy surgery significantly. Further, innovative and promising implants like biozorb LP are also being developed for better outcome for post lumpectomy procedure like breast reconstruction.

Apart from the increased detection of early stage breast cancer, initiatives by government, better reimbursement and insurance and rise in venture capitalist are also some key factors fuelling the lumpectomy market growth. Owing to its superiority over mastectomy, lumpectomy might emerge as the dominant form of breast cancer surgery in the future with market opportunity of more than US$ 10 Billion by 2024.

KuicK Research report on the US lumpectomy market provides a detailed insight into the current market size, trends, opportunities and market dynamics. The report is an outcome of extensive research done on multiple factors governing the US lumpectomy market ranging from cost analysis of lumpectomy procedure, technology & tools involved to key industrial developments that are bound to impact the lumpectomy market. Finally, KuicK Research analysis of forecast and projections regarding the future of lumpectomy market indicate an exciting opportunity waiting in this highly profitable segment of breast cancer surgery.

Table of Contents

1. Prologue to Breast Cancer & Lumpectomy

  • 1.1 Lumpectomy - A Breast Conserving Strategy
  • 1.2 A Safer & Efficient Alternative to Mastectomy

2. Lumpectomy - Opportunities in the US Breast Cancer Therapy Market

  • 2.1 US Breast Cancer Market Size
  • 2.2 Increasing Breast Cancer Incidence in the US
  • 2.3 Combination of Lumpectomy & Radiation- Equivalent Efficacy to Mastectomy
    • 2.3.1 Mastectomy v/s Lumpectomy Preference in American Women
    • 2.3.2 Overall Survival & Recurrence Rates

3. Lumpectomy - Procedure & Cost Involved

  • 3.1 Breast Cancer Mammogram & Biopsy Cost
  • 3.2 Cost Involved During the Procedure
    • 3.2.1 Lumpectomy plus Whole-Breast Radiation Therapy
    • 3.2.2 Lumpectomy plus Partial-Breast Radiation Therapy (Brachytherapy)
  • 3.3 Lumpectomy & Mastectomy Reimbursement Analysis
  • 3.4 Post Lumpectomy Costs
  • 3.4.1 Mastectomy or Mastectomy Plus Reconstruction
  • 3.4.2 Additional Cost (Consumable, Lab, Imaging & Other Service Cost)
  • 3.5 Cost Effectiveness of Lumpectomy

4. Current Market Scenario & Trends in Lumpectomy Breast Cancer Treatment

  • 4.1 Increasing Breast Cancer Screening among American Women
    • 4.1.1 Entry of Advanced Breast Imaging Techniques
    • 4.1.2 Rising Awareness Regarding Breast Cancer Screening
    • 4.1.3 Breast Cancer Incidence & Lumpectomy Preference in Men
  • 4.2 Increasing Clinical Studies Proving Better Efficacy of Lumpectomy

5. Lumpectomy Market Analysis by Technology

  • 5.1 MarginProbe - An Intra Operative Technology to Improve Lumpectomy
  • 5.2 Savi Scout-Breast Localization and Surgical Guidance System
  • 5.3 Biozorb LP for Better Cosmetic Outcome after Lumpectomy

6. Key Developments Affecting the US Lumpectomy Market

  • 6.1 Focus of Key Industries in Early Stage Breast Cancer Segment
  • 6.2 Introduction of Better Breast Cancer Screening Technology & Its Impact on the Lumpectomy Market
  • 6.3 Expansion of US Lumpectomy Technology & Products to Global Platforms
    • 6.3.1 iCAD Early Breast Cancer Screening Technology
    • 6.3.2 Intrabeam System by Carl Zeiss Meditech

7. New & Better Breast Imaging Technology Driving Lumpectomy Market

  • 7.1 Digital Breast Tomosynthesis (DBT)
  • 7.2 Breast Cancer Genetic Screening Tests on the Rise
  • 7.3 FDA Approval of Innovative Lumpectomy Technology
  • 7.4 Magnetic MaMaLoc Technology - Localized Lumpectomy Procedure

8. Presence of Venture Capitalist influencing the US Breast Cancer Lumpectomy Segment

9. Porter's Five Force Analysis of the Breast Lumpectomy Market

  • 9.1 Threat of New Entrant
  • 9.2 Bargaining Power of Patient
  • 9.3 Bargaining Power of Service Providers
  • 9.4 Intensity of Competitive Rivalry
  • 9.5 Threat of Substitutes Procedures

10. Lumpectomy Market Analysis by End User

  • 10.1 Hospitals
  • 10.2 Oncology Research & Screening Centers

11. US Lumpectomy Market Dynamics

  • 11.1 Market Driving Parameters
  • 11.2 Market Growth & Acceptability Challenges

12. Future Forecast & Projections of the Lumpectomy Market

13. Competitive Analysis

  • 13.1 Carl Zeiss Meditech
  • 13.2 Cianna Medical
  • 13.3 Clear Cut Medical
  • 13.4 Dune Medical Devices
  • 13.5 Endomagnetics
  • 13.6 Focal Therapeutics
  • 13.7 Hologic
  • 13.8 iCAD
  • 13.9 Medtronic
  • 13.10 Sanarus

List of Figures

  • Figure 1-1: Overview of Lumpectomy
  • Figure 1-2: Treatment Algorithm in Early Breast Cancer Patients
  • Figure 1-3: Global-Five Year Survival Rate in Breast Cancer by Stage
  • Figure 1-4: Lumpectomy v/s Mastectomy Overview
  • Figure 2-1: US v/s Rest of the World - Breast Cancer Market Size (%), 2018
  • Figure 2-2: US - Breast Cancer Prevalence & Incidence (Patients/Year), 2016-2018
  • Figure 2-3: US - Probability of Developing Breast Cancer in Women by Age(%), 2018
  • Figure 2-4: US - Probability of Breast Cancer by Ethnicity (%), 2018
  • Figure 2-5: Lumpectomy & Mastectomy - Estimated Market Size (%), 2018
  • Figure 2-6: US - Mastectomy v/s Lumpectomy Preference (%) , 2018
  • Figure 2-7: US - Five Year Survival Rate in Women (%), 2018
  • Figure 2-8: US - Five Year Survival Rate in Men (%), 2018
  • Figure 2-9: Efficacy of Lumpectomy v/s Mastectomy (%)
  • Figure 3-1: US - Lumpectomy Treatment Cost by Stage of Breast Cancer (US$/Patient), 2018
  • Figure 3-2: US - Lumpectomy Breast Surgery Cost (US$), 2018
  • Figure 3-3: Lumpectomy - General Overview of the Procedure
  • Figure 3-4: US - Mammogram Cost Analysis (US$/Test), 2018
  • Figure 3-5: US- Biopsy & Mammography Cost (US$/Patient), 2018
  • Figure 3-6: Recent Alternatives to Breast Cancer Biopsy
  • Figure 3-7: US - ONCOblot & Thermography Cost Analysis (US$), 2018
  • Figure 3-8: US - Whole Breast & Partial Breast Radiation Therapy Cost Analysis (US$), 2018
  • Figure 3-9: US - Average Lumpectomy plus Whole Breast Radiation Cost (US$), 2018
  • Figure 3-10: Intrabeam - Single Dose Radiation Therapy Cost Analysis (US$), 2018
  • Figure 3-11: US - Lumpectomy plus Breast Radiation Cost (US$), 2018
  • Figure 3-12: US - Mastectomy & Lumpectomy Reimbursement Analysis (US$), 2018
  • Figure 3-13: US - Breast Reconstruction Surgery Cost (US$), 2018
  • Figure 3-14: US - Breast Reconstruction Cost Post Lumpectomy (US$), 2018
  • Figure 3-15: US - Average Consumable, Lab & Additional Service Cost in Lumpectomy (US$/Patient), 2018
  • Figure 3-16: Comparative Cost Analysis of Mastectomy & Lumpectomy (US$), 2018
  • Figure 4-1: US - USPTF Estimated Screening Cost (US$ Billion)
  • Figure 4-2: US - Digital Mammography System Equipment Cost (US$), 2018
  • Figure 4-3: US - Epidemiology (Estimate) of Breast Cancer by Gender, 2018
  • Figure 5-1: Marginprobe - A Recent Advancement in the Lumpectomy Segment
  • Figure 5-2: MargineProbe - Clinical Efficacy Data proving it Efficacy (%), 2018
  • Figure 5-3: MarginProbe - Breast Re-Excision Reduction Rate (%), 2018
  • Figure 5-4: Savi Scout - Feature Overview
  • Figure 6-1: Sentimag - Key Features in Lumpectomy
  • Figure 6-2: Intrabeam - An Insight into its Key Features
  • Figure 6-3: US v/s Rest of the World-Intrabeam Centers (Number), 2018
  • Figure 7-1: Advantages of Novel Breast Tomography Technique over 2D Technology
  • Figure 7-2: Magnetic MaMaLoc Technology - Overview
  • Figure 8-1: US - Emerging Markets Affecting the Lumpectomy Segment
  • Figure 9-1: US - Lumpectomy Marker - Porter's Five Force Analysis
  • Figure 10-1: US - Recommended Frequency of Breast Cancer Screening by Age
  • Figure 10-2: US - Lumpectomy Market Size by End User (%), 2018
  • Figure 10-3: US - Out Patient Department Visits for Breast Cancer (Patients/State), 2017
  • Figure 10-4: US - Lumpectomy & Mastectomy Payment Source Analysis by Patients (Number), 2017
  • Figure 10-5: US - Cancer Research Funds across Major Research Centers (US$ Million), 2017
  • Figure 11-1: Driving Factors of the Lumpectomy Market
  • Figure 11-2: US - Lumpectomy Market Challenges
  • Figure 12-1: US - Lumpectomy Market Opportunity (US$ Billion), 2018 - 2024
Back to Top
전화 문의